| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,460,000 |
| Market
Cap: |
60.38(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.9301 - $2.54 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 4.4 |
| Insider 6 Months : 4.4 |
| Insider 3/6 Months : 9.1 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Personalis provides genetic tests for cancer. Co. also provides sequencing and data analysis services to support population sequencing initiatives. Co. operates and manages its business as one reportable operating segment, which is the sale of sequencing and data analysis services. Co.'s products include NeXT Platform, which is a platform that enable the analysis of both a tumor and its microenvironment from a single sample. Co. has created an ecosystem of products and capabilities built on the NeXT Platform: ImmunoID Next (tumor profiling from tissue), NeXT Liquid Biopsy (tumor profiling from plasma) and NeXT Personal (liquid biopsy providing for personalized tumor tracking for patients).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
10,000 |
10,000 |
10,000 |
10,000 |
| Total Buy Value |
$16,700 |
$16,700 |
$16,700 |
$16,700 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
4,523 |
22,702 |
41,220 |
125,853 |
| Total Sell Value |
$6,197 |
$31,075 |
$69,252 |
$323,597 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
1 |
9 |
17 |
49 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Chen Richard |
Chief Scientific Officer |
• – – |
2021-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
76,372 |
|
- |
|
| Tachibana Aaron |
Chief Financial Officer |
• – – |
2021-05-15 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
187,823 |
|
- |
|
| Macquitty Jonathan |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
2,736 |
2,736 |
|
- |
|
| Ludlum Ken |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
2,736 |
32,736 |
|
- |
|
| Bowman A Blaine |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
2,736 |
2,736 |
|
- |
|
| Colowick Alan |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
2,736 |
2,736 |
|
- |
|
| Myers Woodrow A Jr |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
2,736 |
5,346 |
|
- |
|
| Eastham Karin |
Director |
– • – |
2021-05-14 |
4 |
A |
$0.00 |
$0 |
D/D |
2,736 |
2,736 |
|
- |
|
| Tachibana Aaron |
Chief Financial Officer |
• – – |
2021-03-17 |
4 |
S |
$26.73 |
$65,382 |
D/D |
(2,446) |
167,823 |
|
26% |
|
| Chen Richard |
Chief Scientific Officer |
• – – |
2021-03-17 |
4 |
S |
$26.73 |
$30,205 |
D/D |
(1,130) |
83,317 |
|
26% |
|
| Myers Woodrow A Jr |
Director |
– • – |
2021-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,610 |
2,610 |
|
- |
|
| Tachibana Aaron |
Chief Financial Officer |
• – – |
2021-03-02 |
4 |
S |
$32.60 |
$98,517 |
D/D |
(3,022) |
170,269 |
|
25% |
|
| Chen Richard |
Chief Scientific Officer |
• – – |
2021-03-02 |
4 |
S |
$32.60 |
$11,247 |
D/D |
(345) |
84,447 |
|
25% |
|
| Chen Richard |
Chief Scientific Officer |
• – – |
2021-02-01 |
4 |
AS |
$38.12 |
$1,546,993 |
D/D |
(40,000) |
84,792 |
|
-44% |
|
| Chen Richard |
Chief Scientific Officer |
• – – |
2021-02-01 |
4 |
OE |
$0.44 |
$5,906 |
D/D |
13,422 |
98,214 |
|
- |
|
| Tachibana Aaron |
Chief Financial Officer |
• – – |
2020-12-17 |
4 |
S |
$36.37 |
$86,961 |
D/D |
(2,391) |
173,291 |
|
34% |
|
| Chen Richard |
Chief Scientific Officer |
• – – |
2020-12-17 |
4 |
S |
$36.37 |
$39,534 |
D/D |
(1,087) |
111,370 |
|
34% |
|
| Tachibana Aaron |
Chief Financial Officer |
• – – |
2020-12-02 |
4 |
S |
$27.76 |
$81,226 |
D/D |
(2,926) |
175,682 |
|
20% |
|
| Chen Richard |
Chief Scientific Officer |
• – – |
2020-12-02 |
4 |
AS |
$27.76 |
$8,134 |
D/D |
(293) |
112,457 |
|
-20% |
|
| Chen Richard |
Chief Scientific Officer |
• – – |
2020-12-01 |
4 |
AS |
$27.75 |
$1,119,989 |
D/D |
(40,000) |
112,750 |
|
-17% |
|
| Chen Richard |
Chief Scientific Officer |
• – – |
2020-12-01 |
4 |
OE |
$0.44 |
$17,600 |
D/D |
40,000 |
152,750 |
|
- |
|
| Abingworth Llp |
Former 10% Owner |
– – – |
2020-10-20 |
4 |
S |
$27.66 |
$3,609,243 |
I/I |
(130,486) |
3,753,340 |
|
-15% |
|
| Abingworth Llp |
10% Owner |
– – • |
2020-10-19 |
4 |
S |
$27.86 |
$5,472,345 |
I/I |
(196,423) |
3,883,826 |
|
-17% |
|
| Abingworth Llp |
10% Owner |
– – • |
2020-10-16 |
4 |
S |
$26.68 |
$2,513,736 |
I/I |
(94,218) |
4,080,249 |
|
-16% |
|
| Abingworth Llp |
10% Owner |
– – • |
2020-10-15 |
4 |
S |
$26.32 |
$97,384 |
I/I |
(3,700) |
4,174,467 |
|
-21% |
|
196 Records found
|
|
Page 6 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.08 (4.85%) 
